{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:27:57Z","timestamp":1791192477388,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"crossref","award":["14282"],"award-info":[{"award-number":["14282"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.cllc.2017.05.016","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T22:03:08Z","timestamp":1496354588000},"page":"93-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study"],"prefix":"10.1016","volume":"19","author":[{"given":"Sara","family":"Pilotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Vaval\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Follador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Piovano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Zilembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Casartelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ardizzoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Barzelloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovenzio","family":"Genestreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mucciarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginio","family":"Filipazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Rijavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Spitaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2017.05.016_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib2","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2017.05.016_bib3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non\u2013small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2017.05.016_bib4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.05.016_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1349-7006.2007.00607.x","article-title":"Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer","volume":"98","author":"Mitsudomi","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2017.05.016_bib6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non\u2013small-cell lung cancer and metastatic colorectal cancer","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.05.016_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2017.05.016_bib10","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.cllc.2017.05.016_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/annonc\/mdt573","article-title":"Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing","volume":"25","author":"Yu","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2013.01.018","article-title":"Uncommon epidermal growth factor receptor mutations in non\u2013small-cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance","volume":"80","author":"Massarelli","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2017.05.016_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2016.02.011","article-title":"BE-POSITIVE: beyond progression after tyrosine kinase inhibitor in EGFR-positive non\u2013small-cell lung cancer patients: results from a multicenter Italian observational study","volume":"95","author":"Vavala","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2016.01.018","article-title":"EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non\u2013small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China","volume":"96","author":"Xu","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non\u2013small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/JTO.0000000000000492","article-title":"Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma","volume":"10","author":"Lohinai","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ctrv.2013.05.001","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non\u2013small-cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients","volume":"39","author":"Roengvoraphoj","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2017.05.016_bib19","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/JTO.0b013e318227e8c6","article-title":"Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non\u2013small-cell lung cancer harboring rare epidermal growth factor receptor mutations","volume":"6","author":"De Pas","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.lungcan.2012.03.012","article-title":"Efficacy and safety of maintenance erlotinib in Asian patients with advanced non\u2013small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study","volume":"77","author":"Wu","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib22","first-page":"126","article-title":"Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond","volume":"4","author":"Khoo","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2017.05.016_bib23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1158\/1078-0432.CCR-13-0169","article-title":"Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes","volume":"19","author":"Oxnard","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.05.016_bib24","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1038\/onc.2008.71","article-title":"EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids","volume":"27","author":"Chen","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2017.05.016_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e3182781e35","article-title":"Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors","volume":"8","author":"Kobayashi","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdt418","article-title":"Rare EGFR exon 18 and exon 20 mutations in non\u2013small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network","volume":"25","author":"Beau-Faller","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib27","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-15-1046","article-title":"EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs","volume":"21","author":"Kobayashi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.05.016_bib28","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1158\/1078-0432.CCR-07-5123","article-title":"Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.05.016_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2017.05.016_bib30","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non\u2013small-cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.05.016_bib31","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.bjc.6604068","article-title":"\u2018Classical\u2019 but not \u2018other\u2019 mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non\u2013small-cell lung cancer","volume":"97","author":"Pallis","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib32","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1158\/1078-0432.CCR-08-1455","article-title":"Effects of erlotinib in EGFR mutated non\u2013small-cell lung cancers with resistance to gefitinib","volume":"14","author":"Costa","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.05.016_bib33","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non\u2013small-cell lung cancer harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","article-title":"Effectiveness of gefitinib against non\u2013small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q","volume":"9","author":"Watanabe","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.lungcan.2014.12.009","article-title":"The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non\u2013small-cell lung cancer","volume":"87","author":"Arrieta","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2014.11.013","article-title":"Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non\u2013small-cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea","volume":"87","author":"Baek","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.05.016_bib37","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtho.2015.12.107","article-title":"Examining treatment outcomes with erlotinib in patients with advanced non\u2013small-cell lung cancer whose tumors harbor uncommon EGFR mutations","volume":"11","author":"Klughammer","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib38","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1158\/0008-5472.CAN-05-1829","article-title":"Epidermal growth factor-independent transformation of Ba\/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression","volume":"65","author":"Jiang","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2017.05.016_bib39","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-11-2353","article-title":"Clinical outcomes in non\u2013small-cell lung cancers harboring different exon 19 deletions in EGFR","volume":"18","author":"Chung","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.05.016_bib40","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.2147\/OTT.S108242","article-title":"Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non\u2013small-cell lung cancer harboring EGFR exon 20 mutations","volume":"9","author":"Chen","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2017.05.016_bib41","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1097\/JTO.0000000000000221","article-title":"Clinical and in\u00a0vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib","volume":"9","author":"Hellmann","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib42","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/cas.12980","article-title":"Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: what is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?","volume":"107","author":"Banno","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2017.05.016_bib43","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non\u2013small-cell lung cancer: preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib44","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1038\/srep05868","article-title":"Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors","volume":"4","author":"Doss","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2017.05.016_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3892\/mco.2014.455","article-title":"Clinical usefulness of gefitinib for non\u2013small-cell lung cancer with a double epidermal growth factor receptor mutation","volume":"3","author":"Oikawa","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jtho.2016.09.001","article-title":"EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors","volume":"12","author":"Barnet","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib47","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.18632\/oncotarget.3727","article-title":"Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma","volume":"6","author":"Bria","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2017.05.016_bib48","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/JTO.0000000000000671","article-title":"Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas","volume":"10","author":"Eng","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib49","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1097\/JTO.0b013e3182a00e37","article-title":"Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK\/MET\/ROS1 gene copy number","volume":"8","author":"Pilotto","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.05.016_bib50","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cllc.2015.11.004","article-title":"Nonsquamous, non\u2013small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and response to therapy","volume":"17","author":"Ulivi","year":"2016","journal-title":"Clin Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417301651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417301651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:02Z","timestamp":1761505682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730417301651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1525730417301651"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2017.05.016","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2017.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}